Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Watch Beam Therapeutics' latest callBeam Therapeutics (NASDAQ:BEAM) Q4 2025 Earnings Call · Replay · Feb 24Read the transcript of Beam Therapeutics (NASDAQ:BEAM) Q4 2025 Earnings CallStory so far
- Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
- Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
- Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
Earlier from Beam Therapeutics
- Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
- Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
- Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
- Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
- Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
Later from Beam Therapeutics
- Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
- Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
- Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
- Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
- Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Follow Beam Therapeutics into a list and get an email when it puts out news.
Follow Beam Therapeutics